Meditrina Welcomes Senior Vice President of Global Sales to Lead Expansion Efforts and Manage Rapid Growth
Hologic's (NASDAQ:HOLX) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Hologic, Inc.'s (NASDAQ:HOLX) lackluster earnings report last week. We think that the softer headline numbers might be getting counterbalanced by some positive
Hologic Is Maintained at Buy by Argus Research
Hologic Is Maintained at Buy by Argus Research
Argus Adjusts Price Target on Hologic to $95 From $89
Hologic (HOLX) has an average rating of outperform and price targets ranging from $70 to $95, according to analysts polled by Capital IQ.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
A Dive Into Hologic (HOLX) International Revenue Trends and Forecasts
Here Is What to Know Beyond Why Hologic, Inc. (HOLX) Is a Trending Stock
Hologic, Inc.'s (NASDAQ:HOLX) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 38.3x Hologic, Inc. (NASDAQ:HOLX) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E
Analysts Have Conflicting Sentiments on These Healthcare Companies: Community Health (CYH) and Hologic (HOLX)
Lumos Diagnostics Concludes Initial Phase of Development Deal With Hologic for Fetal Fibronectin Test; Shares Jump 6%
Lumos Diagnostics (ASX:LDX) concluded the initial stage of its development agreement, aimed at creating a novel fetal fibronectin (fFN) test for women's health company Hologic, according to a Monday f
Hologic Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Decoding Hologic Inc (HOLX): A Strategic SWOT Insight
Hologic Is Maintained at Overweight by JP Morgan
Hologic Is Maintained at Overweight by JP Morgan
Earnings Call Summary | Hologic(HOLX.US) Q2 2024 Earnings Conference
The following is a summary of the Hologic, Inc. (HOLX) Q2 2024 Earnings Call Transcript:Financial Performance:Hologic reported Q2 total revenue of $1.02 billion and non-GAAP earnings per share of $1.0
Hologic, Inc. (NASDAQ:HOLX) Q2 2024 Earnings Call Transcript
Research Alert: CFRA Maintains Hold View On Shares Of Hologic, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our 12-month target price by $5
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
JPMorgan Adjusts Price Target on Hologic to $91 From $85
Hologic (HOLX) has an average outperform rating and price target range of $70 to $95, according to analysts polled by Capital IQ. Price: 76.17, Change: +0.26, Percent Change: +0.34
Express News | Hologic Inc : UBS Raises Target Price to $81 From $79
Express News | Hologic Inc Shares up 2% After Upbeat Q2 Profit